CMS responds to request for information regarding reporting on pharmacy benefits and prescription drug costs
Via Electronic Mail: cschmid@hivhep.org
Carl Schmid
The HIV+Hepatitis Policy Institute
Dear Mr. Schmid,
On behalf of the Centers for Medicare & Medicaid Services (CMS), thank you for the letter regarding the Request for Information (RFI) Regarding Reporting on Pharmacy Benefits and Prescription Drug Costs1. The 58 organizations that signed this correspondence are the voice for many individuals who rely on affordable prescription drugs to treat their health conditions and prevent others, and we appreciate hearing from you on this important issue.
The RFI comment period closed on July 23, 2021, and we thank you for your comments. Input from our stakeholders is an important contribution to our policy-making process, and we value your feedback.
Thank you again for your letter and taking time to share your recommendations.
Sincerely,
Ellen Montz, Ph.D.
Deputy Administrator and Director
Center for Consumer Information & Insurance Oversight Centers for Medicare & Medicaid Services
1 Request for Information Regarding Reporting on Pharmacy Benefits and Prescription Drug Costs, 86 Fed. Reg. 32813 (June 23, 2021), available at: https://www.federalregister.gov/documents/2021/06/23/2021- 13138/request-for-information-regarding-reporting-on-pharmacy-benefits-and-prescription-drug-costs.